IA
ZVRA icon

IFG Advisors’s Zevra Therapeutics ZVRA Stock Holding History

IFG Advisors’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$887K Hold
61,842
– – 0.12% 81
2026
Q1 		$576K Buy
61,842
+32,792
+113% +$296K 0.09% 86
2025
Q4 		$260K Hold
29,050
– – 0.04% 131
2025
Q3 		$276K Hold
29,050
– – 0.05% 127
2025
Q2 		$256K Hold
29,050
– – 0.04% 138
2025
Q1 		$218K Hold
29,050
– – 0.04% 140
2024
Q4 		$242K Buy
29,050
+2,650
+10% +$22.6K 0.05% 127
2024
Q3 		$183K Buy
26,400
+7,700
+41% +$52.3K 0.04% 139
2024
Q2 		$91.6K Hold
18,700
– – 0.02% 135
2024
Q1 		$108K Buy
18,700
+5,800
+45% +$35.7K 0.03% 127
2023
Q4 		$84.5K Hold
12,900
– – 0.02% 124
2023
Q3 		$62.2K Sell
12,900
-1,150
-8% -$5.74K 0.02% 116
2023
Q2 		$71.7K Buy
+14,050
New +$75.7K 0.03% 117

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

IFG Advisors's ZVRA Position: Q2 2026 in Review

IFG Advisors held its Zevra Therapeutics (ZVRA) position steady in Q2 2026 at 61,842 shares worth $887K. The position accounts for 0.12% of the portfolio, ranked #81.

IFG Advisors first reported a position in ZVRA in Q2 2023 and has held it in 13 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • IFG Advisors held 61,842 shares of Zevra Therapeutics worth $887K as of Q2 2026.
  • IFG Advisors left its Zevra Therapeutics share count unchanged in Q2 2026.
  • Zevra Therapeutics made up 0.12% of IFG Advisors's portfolio in Q2 2026, its #81 holding.
  • IFG Advisors first reported a position in Zevra Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on IFG Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.